Navigation Links
OncoSec Initiates Two Additional Clinical Sites for Phase II Metastatic Melanoma Trial
Date:3/14/2012

ed in a year, resulting in approximately 10,000 deaths. Melanoma originates in melanocytes, the cells which produce the pigment melanin that colors our skin, hair, and eyes. The majority of melanomas are black or brown, but often they can also be skin-colored, pink, red, purple, blue or white. Currently, there remains few treatment options for patients with late stage metastatic disease that can extend survival for the broad population.

About OncoSec Medical Inc.

OncoSec Medical Incorporated is a biopharmaceutical company developing its advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease. OMS ElectroOncology therapies address an unmet medical need and represent a potential solution, for less invasive and less expensive therapies that are able to minimize detrimental effects resulting from currently available cancer treatments such as surgery, systemic chemotherapy or immunotherapy and other treatment alternatives.  OncoSec's core technology is based upon its proprietary use of an electroporation platform, the OncoSec Medical System (OMS), to dramatically enhance the delivery and uptake of a locally delivered DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agents (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward
'/>"/>

SOURCE OncoSec Medical Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. OncoSec to Evaluate Potential Predictive or Prognostic Biomarkers for Treatment of Solid Tumor Cancers Using OMS ElectroImmunotherapy
2. OncoSecs OMS ElectroImmunotherapy Technology Platform and its Ongoing Phase II Merkel Cell Carcinoma Clinical Trial Featured in Seattle Newspaper
3. OncoSec Doses First Patient in Phase II Clinical Trial for Metastatic Melanoma
4. OncoSec to Present at World Cancer Immunotherapy Conference
5. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
6. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
7. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
8. OncoSec to Present at Medical Device Investor Forum
9. Device Master File for OncoSec Medical System Completed and Submitted to FDA
10. OncoSec Releases Devices for Use in Clinical Trials
11. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Research and Markets  has announced the addition of the ... offering. http://photos.prnewswire.com/prnh/20130307/600769 ... pain in the human body,s joints such as wrists, fingers, ... the tissues that surround the joints and in other organs. ... usually just mild pain around the joints coupled with stiffness ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
Breaking Medicine Technology:Global Rheumatoid Arthritis Drugs Market 2014-2018 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2
... Feb. 14, 2012 Glenveigh Medical  announced today that ... its request for orphan drug designation for a potential ... compound, digoxin immune fab (ovine) , is an ... toxicity. Glenveigh, a nationally renowned life science company, has ...
... 14, 2012 ZONARE Medical Systems, Inc., a developer ... of Timothy A. Marcotte to President and Chief Executive ... served as Chief Operating Officer with responsibility for the ... the company,s Chief Financial Officer.  Prior to ZONARE, he ...
Cached Medicine Technology:Nationally Recognized Glenveigh Medical Announces Orphan Drug Designation for Treatment for Severe Preeclampsia and Eclampsia 2ZONARE Medical Systems Announces Appointment of Timothy A. Marcotte as President and Chief Executive Officer 2
(Date:7/28/2014)... Cape Regional Medical Center, is ... technology solution in an effort to streamline its ... with their New Jersey health information exchange (NJSHINE). ... in New Jersey, serves the local population and ... of inpatient and outpatient services. With a strong ...
(Date:7/28/2014)... News) -- Endurance runners are far more likely to ... according to a new study. The researchers ... warm climates are actually 10 times more likely to ... common sudden death of a young and apparently healthy ... irregular heartbeat, often gets a lot more media attention. ...
(Date:7/28/2014)... The Oakwood Foundation celebrated a major gift this ... PC that will benefit each community we serve for ... The HBWS group is among the Foundation’s largest physician ... donations. Through their latest gift, they will be one ... Classic for the next 6 years; provide state-of-the-art technology ...
(Date:7/28/2014)... one of two dopamine-producing regions in the brain was ... isoflurane or propofol. In the August issue of ... report that rats anesthetized with continuous doses of either ... up in response to electrical stimulation delivered to the ... major dopamine-releasing area, the substantia nigra, did not induce ...
(Date:7/28/2014)... 2014 The report, “Blowing Agents ... - Trends and Forecasts to 2019” defines and ... and forecasting of the global consumption volume and ... tables with 39 figures spread through 226 Pages ... http://www.marketsandmarkets.com/Market-Reports/blowing-agents-market-71329121.html , Blowing agents are highly utilized ...
Breaking Medicine News(10 mins):Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Heat Stroke a Greater Threat to Endurance Runners Than Heart Problems: Study 2Health News:Stimulation of brain region restores consciousness to animals under general anesthesia 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 2Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 3Health News:Blowing Agents Market is Poised to Reach 452.0 Kilotons at CAGR of 5.8% by 2019 – Report by MarketsandMarkets 4
... ... the story of a David versus Goliath struggle raging in the West, joins ... release in New York City and in Los Angeles (August 7 - 13). ... as part of the Reel Impact series on Planet Green, a network of ...
... , , EAST RUTHERFORD, N.J., Aug. 4 Cambrex ... June 30, 2009. , , Highlights , ... the impact of foreign currency. Reported sales declined by 9.8% for the quarter. ... million in the same quarter last year (see attached table). , ...
... , , WALTHAM, Mass., Aug. 4 ... global leader in enabling individuals to take charge of their ... health management, today announced that it intends to offer $150 ... Payment of the notes will be guaranteed by certain of ...
... issues may lead to unhealthy habits , TUESDAY, Aug. ... Afghanistan conflicts who have mental health problems such as ... for having cardiovascular disease risk factors, a new study ... with PTSD, a common mental health problem among veterans ...
... , , ORRVILLE, Ohio, Aug. 4 ... winners of the Crisco Live Smart, Cook Smarter Contest. ... Puritan (R) Canola Oil with Omega-3 DHA, one grand prize ... awarded $5,000 for kitchen makeovers. , , These five ...
... of cancer, parts of the genetic material of tumor cells ... kind of methyl labeling ranges among the epigenetic changes that ... labels are found particularly often in genes which act as ... do not know why healthy cells and cancer cells differ ...
Cached Medicine News:Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 2Health News:Premier of Split Estate at DocuWeeks 2009 to Call National Attention to Urban Drilling in New York and Los Angeles 3Health News:Cambrex Reports Second Quarter 2009 Results 2Health News:Cambrex Reports Second Quarter 2009 Results 3Health News:Cambrex Reports Second Quarter 2009 Results 4Health News:Cambrex Reports Second Quarter 2009 Results 5Health News:Cambrex Reports Second Quarter 2009 Results 6Health News:Cambrex Reports Second Quarter 2009 Results 7Health News:Cambrex Reports Second Quarter 2009 Results 8Health News:Cambrex Reports Second Quarter 2009 Results 9Health News:Cambrex Reports Second Quarter 2009 Results 10Health News:Cambrex Reports Second Quarter 2009 Results 11Health News:Cambrex Reports Second Quarter 2009 Results 12Health News:Inverness Medical Innovations, Inc. Announces Offering of $150 Million of Senior Notes 2Health News:Young Vets With PTSD More Prone to Heart Risk Factors 2Health News:Young Vets With PTSD More Prone to Heart Risk Factors 3Health News:Crisco(R) Announces the Crisco Live Smart, Cook Smarter Contest Winners 2Health News:Crisco(R) Announces the Crisco Live Smart, Cook Smarter Contest Winners 3Health News:Silenced genes as a warning sign of blood cancer 2
... The Gellhorn Pessary is used ... degree prolapse, or procidentia. It ... base and comes in nine ... Gellhorn easily folds over for ...
... 450,000 people in,the United States die ... a defibrillation shock,quickly during an episode ... that passes, the chance of,survival decreases ... Association,and JCAHO recommend that AEDs be ...
... The BioArc™ System treats female urinary stress ... using either a suprapubic (BioArc™ SP) or ... is an innovative hybrid system combining synthetic ... hybrid sling currently available. The BioArc utilizes ...
... Proven tension-free sling technology ... porcine acellular collagen matrix sling, ... tissue-to-tissue contact between sling and ... urethral or vaginal abrasion or ...
Medicine Products: